Insights into Photo Degradation and Stabilization Strategies of Antibody–Drug Conjugates with Camptothecin Payloads
<b>Background</b>: Photostability assessment is a critical component in the development of drug products, particularly for antibody-drug conjugates (ADCs) containing light-sensitive small molecules such as camptothecin (CPT) and its derivatives. ADCs conjugated with CPT derivative payloads often require extensive formulation and drug product development to ensure product stability due to their unique light-induced degradation pathways. In this study, we assessed the photostability of two ADC molecules with a CPT derivative payload (deruxtecan, DXd). <b>Methods</b>: Following light exposure, the stability of ADCs was assessed by examining critical quality attributes, such as aggregation and photodegradation products of the antibody, payload, and formulation excipients, using advanced liquid chromatography and mass spectrometry techniques. <b>Results</b>: Our results revealed key degradation pathways, including the formation of high-molecular-weight (HMW) species, payload degradation, and post-translational modifications (PTMs) on amino acid residues in the antibodies. Additionally, the DXd payload amplified the photosensitivity of the formulation solution, leading to histidine degradation in the formulation buffer and subsequent pH changes. To enhance the stability of ADCs for manufacturing and therapeutic use, we developed a robust formulation by systematic buffer screening and a targeted evaluation of selected antioxidant excipients. Further investigations into light conditions revealed that DXd ADCs are particularly sensitive to short-wavelength light. When evaluating the container closure system, it was demonstrated that using amber vials is a viable option for protecting against light-induced degradation. <b>Conclusions</b>: This report outlines a comprehensive strategy to address photo instability in DXd ADC drug product development, focusing on formulation optimization, controlled manufacturing light settings, and the option of using protective containers to ensure product stability.
Authors
- Dingjiang Liu (ORCID: https://orcid.org/0000-0002-8665-2426)
- Babatunde O. Olagunju (ORCID: https://orcid.org/0009-0009-2610-3802)
- Yimeng Zhao (ORCID: https://orcid.org/0000-0002-4217-7061)
- Mohammed Shameem (ORCID: https://orcid.org/0000-0001-7289-8380)
- Senlin Luo (ORCID: https://orcid.org/0000-0002-3310-8312)
- Wenhua Wang (ORCID: https://orcid.org/0009-0008-1539-4707)
- Yue Su (ORCID: https://orcid.org/0000-0002-4388-7452)
- Xiao Pan (ORCID: https://orcid.org/0000-0002-4444-8275)
- Haibo Qiu (ORCID: https://orcid.org/0000-0002-8449-4233)
- Joshua Bulos
- Ricky Uroza
Institutions
- State University of New York (US)
- SUNY College of Environmental Science and Forestry (US)
- Regeneron (United States) (US)
- York University (US)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-10-28
- DOI
- https://doi.org/10.3390/pharmaceutics17111397
- Primary Topic
- Safe Handling of Antineoplastic Drugs
- Type
- article
- Field-Weighted Citation Impact
- 0.00